Spots Global Cancer Trial Database for Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
Official Title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Tarlatamab Therapy in Subjects With Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Who Have Not Progressed Following Concurrent Chemoradiation Therapy
Study ID: NCT06117774
Study Description
Brief Summary: The primary objective of this study is to compare the efficacy of tarlatamab with placebo as assessed by progression free survival (PFS).
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Our Lady of the Lake Cancer Institute, Baton Rouge, Louisiana, United States
Laura and Isaac Perlmutter Cancer Center at New York University Langone, New York, New York, United States
FirstHealth Cancer Center, Pinehurst, North Carolina, United States
West Virginia University Health Sciences Center, Morgantown, West Virginia, United States
Fiona Stanley Hospital, Murdoch, Western Australia, Australia
Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, Fujian, China
Tongji Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China
Hubei Cancer Hospital, Wuhan, Hubei, China
Shandong Provincial Cancer Hospital, Jinan, Shandong, China
Shanxi Bethune Hospital, Taiyuan, Shanxi, China
Zhejiang Taizhou Hospital, Taizhou, Zhejiang, China
National Hospital Organization Nagoya Medical Center, Nagoya-shi, Aichi, Japan
National Cancer Center Hospital East, Kashiwa-shi, Chiba, Japan
National Hospital Organization Shikoku Cancer Center, Matsuyama-shi, Ehime, Japan
Kurume University Hospital, Kurume-shi, Fukuoka, Japan
National Hospital Organization Hokkaido Cancer Center, Sapporo-shi, Hokkaido, Japan
Kanagawa Prefectural Hospital Organization Kanagawa Cancer Center, Yokohama-shi, Kanagawa, Japan
Sendai Kousei Hospital, Sendai-shi, Miyagi, Japan
Niigata Cancer Center Hospital, Niigata-shi, Niigata, Japan
Okayama University Hospital, Okayama-shi, Okayama, Japan
Kansai Medical University Hospital, Hirakata-shi, Osaka, Japan
Osaka International Cancer Institute, Osaka-shi, Osaka, Japan
Kindai University Hospital, Osakasayama-shi, Osaka, Japan
Saitama Medical University International Medical Center, Hidaka-Shi, Saitama, Japan
Saitama Cancer Center, Kitaadachi-gun, Saitama, Japan
Shizuoka Cancer Center, Sunto-gun, Shizuoka, Japan
Dokkyo Medical University Hospital, Shimotsuga-gun, Tochigi, Japan
Juntendo University Hospital, Bunkyo-ku, Tokyo, Japan
Chungbuk National University Hospital, Cheongju Chungbuk, , Korea, Republic of
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, , Taiwan
Taipei Veterans General Hospital, Taipei, , Taiwan
Izmir Ekonomi Universitesi Medical Point Hastanesi, Izmir, , Turkey
Kocaeli Universitesi Tip Fakultesi Hastanesi, Kocaeli, , Turkey
Medical Park Seyhan Hastanesi, Mersin, , Turkey
Contact Details
Name: MD
Affiliation: Amgen
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
